Means and frequencies of participants' characteristics by androgen receptor status (N = 1467), Nurses' Health Study (1976–1997)
| Characteristic | AR− | AR+ |
|---|---|---|
| n (%) | 313 (21.3) | 1154 (78.7) |
| Age at diagnosis, mean (n), y | 59.0 (313) | 60.8 (1154) |
| BMI at diagnosis, mean (na), kg/m2 | 26.6 (280) | 26.0 (1041) |
| Smoking, na (%) | ||
| Never | 138 (44.2) | 442 (38.5) |
| Past | 125 (40.1) | 482 (42.1) |
| Current | 49 (15.7) | 222 (19.4) |
| ER status, n (%) | ||
| Positive | 140 (44.7) | 1024 (88.7) |
| Negative | 173 (55.3) | 130 (11.3) |
| PR status, na (%) | ||
| Positive | 114 (36.7) | 830 (72.2) |
| Negative | 197 (63.3) | 319 (27.8) |
| HER2 status, na (%) | ||
| Positive | 46 (15.0) | 81 (7.1) |
| Negative | 260 (85.0) | 1059 (92.9) |
| Nodal involvement, n (%) | ||
| None | 212 (67.7) | 883 (76.5) |
| 1–3 | 78 (24.9) | 220 (19.1) |
| 4–9 | 16 (5.1) | 28 (2.4) |
| ≥10 | 7 (2.3) | 23 (2.0) |
| Tumor size (cm), n (%) | ||
| ≤2 | 188 (60.1) | 814 (70.5) |
| >2 | 125 (39.9) | 340 (29.5) |
| Histological grade, n (%) | ||
| I (low) | 22 (7.0) | 302 (26.2) |
| II (intermediate) | 127 (40.6) | 692 (60.0) |
| III (high) | 164 (52.4) | 160 (13.8) |
| Stageb, n (%) | ||
| I | 154 (49.2) | 682 (59.1) |
| II | 126 (40.3) | 394 (34.1) |
| III | 33 (10.5) | 78 (6.8) |
| Chemotherapy, na (%) | ||
| Yes | 141 (55.7) | 258 (27.4) |
| No | 112 (44.3) | 682 (72.6) |
| Hormone treatment, na (%) | ||
| Yes | 145 (58.2) | 672 (71.3) |
| No | 104 (41.8) | 270 (28.7) |
| Radiation treatment, na (%) | ||
| Yes | 114 (45.4) | 393 (41.6) |
| No | 137 (54.6) | 551 (58.4) |
an does not add to total because of missing information.
bStage I: tumor size ≤ 2 cm and no nodal involvement;
stage II: tumor size ≤ 2 cm and 1–3 nodes or 2–4 cm and 0–3 nodes or 4+ cm and 0 nodes;
stage III: tumor size ≤ 2 cm and 4+ nodes or 2–4 cm and 4+ nodes or >4 cm and 1+ nodes.